BMI-1026 is a synthetic aminopyrimidine compound that targets cyclin dependent kinases (cdks) and was initially designed as a potential anticancer drug. Even though it has been well documented that BMI-1026 is a potent cdk inhibitor, little is known about the cellular effects of this compound. In this study, we examined the effects of BMI-1026 treatment on inducing premature senescence and then evaluated the biochemical features of BMI-1026-induced premature senescence. From these experiments we determined that BMI-1026 treatment produced several biochemical features of premature senescence and also stimulated expression of mitogen activated protein kinase (MAPK) family proteins. BMI-1026 treatment caused nuclear translocation of activated Erk1/2 and the formation of senescence associated heterochromatin foci in 5 days. The heterochromatin foci formation was perturbed by inhibition of Erk1/2 activation. [BMB reports 2008; 41(7): 523-528]
INTRODUCTION
After a given finite number of replications, normal human diploid fibroblasts (HDFs) cease to divide and enter a replicatively arrested state called replicative senescence (1) . In replicative senescence the shortened telomere activates the DNA-damage checkpoint kinase pathway, which results in cell cycle progression arrest by inhibiting cdks (2) (3) (4) (5) . Although telomere erosion can induce the DNA damage response pathway-activated cell cycle arrest, senescence is not a simple end result of telomere shortening. The cumulative influences of other factors are required for launching the senescence program. The other type of senescence called "premature senescence" is triggered by activation of cellular oncogenes, reactive oxygen species, DNA damages and exposure to cytotoxic stress, and/or various kinds of toxic compounds (6, 7) . Senescence is believed to be one of the defense mechanisms that protect normal cells from tumorous change (8) . The senescent cell displays typical phenotypes including absence of mitosis, enlarged flattened morphology, increased senescence associated β-galactosidase (SA-β-gal) activity, and the formation of a distinct chromatin structure known as senescence associated heterochromatin foci (SAHF) (9, 10) . Except for the fact that the chromatin remodeling machinery and histone chaperones participate in SAHF formation, the signaling pathway and mechanisms of SAHF formation are still under investigation (11) . BMI-1026 is an aminopyrimidine compound, which was synthesized in an attempt to discover anticancer drugs that target cyclin dependent kinases (12, 13) . In vitro kinase assays have determined that BMI-1026 potently inhibits cdk1, cdk2 and cdk5 at nanomolar concentrations, while no effects on other kinases including Erk1, PKCδ, PKA, Plk1, and Aurora A have been observed (12) . Even though it has been well documented that BMI-1026 is a potent cdk inhibitor, very little work has been done to examine the cellular effects of BMI-1026 treatment. In this study, the effects of BMI-1026 treatment on inducing premature senescence were examined and the characteristics of the premature senescence phenotype resulting from BMI-1026 treatment were evaluated. Although a multitude of factors can cause senescence, which is the outcome of premature senescence or inhibition of cell cycle progression, the cause and effect relationships between complex features of senescence and direct inhibition of cdk is still unclear. Here, we report that BMI-1026 treatment activated Erk1/2 and induced both SAHF formation and premature senescence in HDFs.
RESULTS AND DISCUSSION

Sub-lethal treatment can induce SA-β-gal activities and caveolin-1 expression
Young HDF cells were treated with 50 nM, 100 nM, and 200 nM concentrations of BMI-1026 for the indicated time periods. As a negative control, HDF cells were treated with dimethyl sulfoxide (DMSO) alone. In HDF cells treated with 100 nM and 200 nM BMI-1026, population doubling was not observed. Since increased SA-β-gal activity is a characteristic marker observed in senescence cells (9) , we examined the influence of BMI-1026 treatment on SA-β-gal activity. Around 40% of cells treated with BMI-1026 showed increased SA-β-gal activity, and these increases occurred in a concentration and time depend-http://bmbreports.org ent manner (Fig. 1A and B) , whereas the negative control showed no change in activity. In addition, cells that were treated with 200 nM BMI-1026 showed more SA-β-gal activities than those treated with 100 nM, however, a large number of apoptotic cells were also observed (Fig. 1A) . We then examined the changes of other senescence markers including caveolin-1, and transglutaminase 2 (14-16). BMI-1026 treatment (50 nM and 100 nM) induced the accumulation of caveolin-1 within 4 days (Fig. 1C ), but accumulation of transglutaminase 2 was not observed, indicating that the accumulation of this protein is a secondary result of senescence and is not directly related with the inhibition of cdks. However the status of caveolin-1 is closely related with the inhibition of cdks. BMI-1026 treated cells showed cell cycle progression arrest at G2/M phase (Fig. 1D) . As no mitotic cells were observed, the cells were arrested in G2 phase prior to mitosis.
BMI-1026 treatment can activate MAPK family of proteins
It has been well documented that elevated mitogenic signals (overexpression of ras, raf, and MEK) induce cellular senescence, http://bmbreports.org BMB reports and the activity of Erk1/2 increases in the course of ras or MEK induced senescence (17) (18) (19) . Therefore, we examined the phosphorylation of Erk1/2 and representative MAPK family pathway molecules including MEK, p38 MAPK, and SAPK/JNK in BMI-1026 treated HDF cells. Direct inhibition of cdks by BMI-1026 resulted in the activation of Erk1/2, p38 MAPK, and SAPK/JNK ( Fig. 2A) . In addition, phosphorylation of Erk1/2 and SAPK/JNK persisted for up to 5 days, whereas phosphorylation of p38 MAPK decreased after 3 days. Although, the decreased level was still higher than that of untreated young cells. Activation of the MAPK family pathway by BMI-1026 treatment was quite different from a recent report which examined the effect of flavopiridol, one of most widely studied cdk inhibitor. In this study flavopiridol treatment was shown to eliminate MAPK family pathway activation upon the treatment of TNF (20) .
Immediate changes in Erk1/2 and p38 MAPK phosphorylation, and the effects of MEK inhibitor on Erk1/2 phosphorylation
Since BMI-1026 treatment elicited prolonged phosphorylation of Erk1/2 and p38 MAPK, we wanted to determine the immediate effects of BM-1026 on these proteins. To eliminate serum induced non-specific phosphorylation of MAPKs, we cultivated HDF cells in serum free media for 24 h prior to treatment with BMI-1026. Treatment with BMI-1026 triggered phosphorylation of Erk1/2 and p38 MAPK in a biphasic pattern (Fig. 2B) . The early phase activation of Erk1/2 and p38 MAPK was also observed in DMSO treated control cells (data not shown). The second sustained activation of Erk1/2 and p38 MAPK, which was not observed in DMSO treated cells, occurred within 3 h and persisted for 24 h. Since phosphorylation of Erk1/2 can be triggered by activation of MEK, we wanted to determine whether the MEK1 inhibitor, U-0126, could suppress BMI-1026 induced phosphorylation of Erk1/2 (21). Pretreatment with 10 μM U-0126 did suppress the phosphorylation of Erk1/2 to a basal level; however, it did not completely eliminate phosphorylation (Fig. 2C) . It is unclear why Erk1/2 is activated by treatment of BMI-1026, but our results suggest that upstream kinase activities may activate Erk1/2 proteins under a state of direct inhibition of cdks.
BMI-1026 treatment induces translocation of activated Erk1/2 and SAHF formation
To convey an activated mitogenic signal to the nucleus, nuclear translocation of activated Erk1/2 is essential (22) . In terminally replicative senescent HDFs the nuclear Erk1/2 activities are significantly impaired upon mitogenic stimuli (23) . We conducted phospho-Erk1/2 immunofluorescence staining to determine whether activated Erk1/2 could migrate to the nucleus. The phosphorylated Erk1/2 accumulated in the nuclear membrane region after the first day of treatment, and then began to translocate to the nucleus on the third day (Fig.  3) . Surprisingly, BMI-1026 treatment induced SAHF formation on the fifth day, and the occurrence of SAHF coincided with the appearance of a prominent nuclear localization signal of http://bmbreports. activated Erk1/2. DMSO treatment did not induce SAHF formation. SAHF formation was observed in more than 40% of the cells after 5 days of BMI-1026 treatment and the intensity of SAHF was enhanced with prolonged treatment. Although SAHF occurred after 5 days of BMI-1026 treatment, BMI-1026 treated cells could re-enter the cell replication cycle after removal of the compound, which was also resulted in the disappearance of SAHF (Fig. 3) . To investigate whether Erk1/2 activation by BMI-1026 treatment is responsible for SAHF formation, young HDF cells were treated simultaneously with BMI-1026 and U-0126 for 1 week and the numbers of cells with SAHF were determined. Inhibition of MEK by U-0126 perturbed BMI-1026 induced SAHF formation ( Table 1 ). The SAHF formation by treatment of BMI-1026 was closely related with activation and nuclear translocation of Erk1/2, indicating that activated Erk1/2 may potentially collaborate with histone chaperones or chromatin-remodeling machinery for senescence related chromatin modification (11) . Based on these results we can conclude that direct inhibition of cdks by BMI-1026 treatment can produce premature senescence, including activation of SA-β-gal, accumulation of caveolin-1, activation of Erk1/2 kinase pathway and formation of SAHF. BMI-1026 induced SAHF formation via activation of Erk1/2 is the first experiment to demonstrate that a cdk inhibitor can induce SAHF formation, thus BMI-1026 may be a useful compound for the study of senescence related chromatin dynamics. In addition, since senescence is known barrier to cancerous transformation and given that cancer cells which develop from senescent cells commonly show retarded proliferation (8) , direct inhibition of cdks may still represent a promising anticancer therapeutic approach via the induction of senescence and suppression of rapid proliferation.
MATERIALS AND METHODS
Cell culture and BMI-1026 treatment
HDFs were maintained in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen), 100 units/ml penicillin and streptomycin (Invitrogen) in a humidified 5% CO2 incubator at 37 
SA-β-gal staining
BMI-1026 treated or DMSO treated cells were stained as previously described (9) . Briefly, cells were washed twice with Dulbecco's phosphate buffered saline (DPBS; JBI, Korea) and http://bmbreports.org BMB reports then fixed with 3.7% formaldehyde in DPBS for 5 min. After being washed, the cells were stained overnight at 37 o C with a solution of 5-bromo-4-chloro-3-indolyl β-D-galactoside (X-gal) containing 1 mg/ml X-gal, 40 mM sodium citrate buffer (pH 6.0), 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl, and 2 mM MgCl2. The stained cells were then observed and photographed using an Olympus IX 70 microscope equipped with a digital camera.
Flow cytometry
For cell cycle analysis, BMI-1026 treated cells were harvested and fixed with 70% ethanol at -20 o C for more than 4 h and then the nuclei was stained with propidium iodide. Cellular DNA was analyzed by fluorescence-activated cell sorting (FACS) using a BD FACSCalibur (Becton Dickinson, San Jose, CA) according to manufacturer's instructions. Data was analyzed using CellQuestPro TM software (Becton Dickinson).
Western blot
BMI-1026 treated HDF cells were washed with cold DPBS (JBI) and directly lysed by boiling for 5 min in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer consisting of 50 mM Tris-Cl (pH 6.8), 100 mM dithiothreitol, 2% SDS, 0.001% bromophenol blue, and 10% glycerol. 
Immunofluorescence staining
HDF cells were plated onto poly-D lysine (P0899, SigmaAldrich) coated glass coverslips. BMI-1026 was then added at the indicated time periods and concentrations. For immunofluorescence staining, cells were fixed with 3.7% formaldehyde for 5 min and then permeabilized with 0.5% Triton X-100 in DPBS for 5 min. After blocking with 5% bovine serum albumin (BSA), coverslips were incubated with a phospho-Erk1/2 antibody (Cell Signaling Technologies, 1:200) and a α-tubulin antibody (Sigma-Aldrich; 1:500) in a humidified chamber for 2 h. After washing with DPBS containing 1% BSA, the coverslips were incubated with Alexa-488 labeled anti-rabbit antibodies (BD Pharmingen, San Diego, CA; 1:200) and Texas Red conjugated anti-mouse antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA; 1:200). For chromatin visualization, cells were stained with Hoechst 33452 (Sigma-Aldrich; 10 μg/ml). Immunofluorescence stained samples were imaged using a LSM 510 META TM confocal microscope (Carl Zeiss, Thornwood, NY).
